Assessing a composite end point for new tocolytics in clinical trials: Data from 4 US integrated delivery networks

E-ISSN： 1099-1557|27|2|213-220

ISSN： 1053-8569

Source： PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol.27, Iss.2, 2018-02, pp. : 213-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point

By Spagnolo Paolo Luppi Fabrizio

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1139-1146

Future Science

Access to resources Recommend Favorite

Modeling hard clinical end-point data in economic analyses

By Kansal Anuraag R. Zheng Ying Palencia Roberto Ruffolo Antonio Hass Bastian Sorensen Sonja V.

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1327-1343

Informa Healthcare

Access to resources Recommend Favorite

Clinical trials and surrogate end points: lessons from the ENHANCE trial

By Farmer John Alan

Future Lipidology, Vol. 3, Iss. 4, 2008-08 ,pp. : 353-357

Future Medicine

Access to resources Recommend Favorite

Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain

By Silberstein S. D.

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 861-867

Informa Healthcare

Access to resources Recommend Favorite

Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 514-520

John Wiley & Sons Inc

Access to resources Recommend Favorite